Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay

This publication has 33 references indexed in Scilit:

• Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
  BMC Cancer, 2010
• Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
  Journal of Clinical Oncology, 2009
• Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH
  Diagnostic Molecular Pathology, 2009
• A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue
  Diagnostic Molecular Pathology, 2009
• In Reply
  Journal of Clinical Oncology, 2007
• The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
  Journal of Clinical Pathology, 2007
• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
  Journal of Clinical Oncology, 2007
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005
• HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
  JNCI Journal of the National Cancer Institute, 2004
• HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization
  Mayo Clinic Proceedings, 2002